1-3 of 3
Mark J. Cantwell
Close
Sort by
Journal Articles

Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL)

Januario E. Castro, M.D., Lee Schwartzberg, MD, FACP, Javier Pinilla-Ibarz, MD, PhD, Johanna Melo-Cardenas, B.Sc, Juan S. Barajas-Gamboa, M.D., Mark J. Cantwell, PhD, Thomas J. Kipps, M.D., Ph.D
Journal: Blood
Blood (2011) 118 (21): 168.
https://doi.org/10.1182/blood.V118.21.168.168
Published: 2011
Journal Articles

Ad-ISF35- Transduced Autologous Cells Promote In Vitro and In Vivo Chemosensitization to FCR and Durable Complete Responses In Patients with Del(17p)/P53 Defective Chronic Lymphocytic Leukemia.

Januario E Castro, M.D, Johanna Melo-Cardenas, B.Sc, Juan Sebastian Barajas-Gamboa, M.D, Mauricio Urquiza, PhD, Mark J. Cantwell, PhD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 1472.
https://doi.org/10.1182/blood.V116.21.1472.1472
Published: 2010
Journal Articles

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia

Clinical Trials & Observations
William G. Wierda, Mark J. Cantwell, Sandra J. Woods, Laura Z. Rassenti, Charles E. Prussak, Thomas J. Kipps
Journal: Blood
Blood (2000) 96 (9): 2917–2924.
https://doi.org/10.1182/blood.V96.9.2917
Published: 2000